An interventional study of endoscopic ligation and Supra-selective embolization in Epistaxis, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-29.
Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Health services research
Current recommendations consider surgical ligation and supra-selective embolization as equivalent in terms of efficacy and there is no clear consensus to choose between one and the other technique. In the absence of medico-economic studies, these recommendations could not be based on any differences in efficiency between the two techniques. The management of patients with severe non-traumatic epistaxis remains controversial and varies according to the hospital and/or university centers. In practice, the use of one or the other technique depends on the habits of each reference center.
The hypothesis is that early ligation of the sphenopalatine arteries would reduce the costs of care for the community while improving the quality of life of patients compared to supra-elective embolization.
This medico-economic superiority could go through:
96 studies on the registry are indexed under Epistaxis; 22 are open to participants now.
This study's planned enrollment of 180 is above the median of 64 across 81 interventional studies indexed under Epistaxis.
Browse Epistaxis studies →University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For non randomized patient
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: endoscopic ligation
Procedure: Supra-selective embolization
the surgical ligation of one or both sphenopalatine arteries by endoscopic way.
occlusion of the terminal branches of the nasal external carotid artery.
incremental cost-utility ratio
the cost-utility ratio integrating direct medical and non-medical costs
Time frame: Month 18
number of recurrences
Time frame: Month 18
time to first recurrence
Time frame: Month 18
the number of complications
Time frame: Month 18
nature of complications
Time frame: Month 18
quality of life with EQ-5D-5L
Time frame: Month 18
quality of life with SNOT 22
Time frame: Month 18
the number of hospitalizations
Time frame: Month 18
duration of hospitalizations
Time frame: Month 18
the addiction with KATZ scale
Time frame: Month 18
incremental cost-effectiveness ratio
the incremental cost-effectiveness ratio (cost/number of recurrences avoided) from the perspective of the community
Time frame: Month 18
the description of the costs of care
only for non-randomized patients
Time frame: Month 18
financial benefit (1 year)
the annual financial benefit of routine implementation of arterial ligation in the treatment of severe epistaxis, from a community perspective
Time frame: Month 12
financial benefit (5 year)
the 5-year financial benefit of routine implementation of arterial ligation in the treatment of severe epistaxis, from a community perspective
Time frame: Year 5
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.
Of 24 interventional studies with no phase under Epistaxis, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's planned 43 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →